Please use this identifier to cite or link to this item: https://hdl.handle.net/10419/274364 
Year of Publication: 
2022
Citation: 
[Journal:] Journal of Open Innovation: Technology, Market, and Complexity [ISSN:] 2199-8531 [Volume:] 8 [Issue:] 2 [Article No.:] 63 [Year:] 2022 [Pages:] 1-18
Publisher: 
MDPI, Basel
Abstract: 
The advancement of technology in the biopharmaceutical industry has spearheaded the speed and scale of digitalization in various aspects. New drug development is becoming more complex, costly, and challenging. This paper examines how the pharmaceutical value chain model could integrate with the product-life-cycle perspective to better explain the drug development process changes and how the digital transformation could be implemented at each stage of the drug development process. We suggest a new framework to capture digital value creation in the biopharmaceutical industry by focusing on the specific processes in new drug development and integrating the product life cycle management and value chain model. The new framework has operational implications for the biopharmaceutical industry, where digital transformation can simplify and increase the efficiency in each phase, from drug discovery, clinical trials, regulatory, manufacturing, commercialization, to monitoring processes.
Subjects: 
pharmaceutical industry
value chain
product life cycle management
drug developmentprocess
digital transformation
technology adoption
industry transformation
research anddevelopment
open innovation
innovation policy
Persistent Identifier of the first edition: 
Creative Commons License: 
cc-by Logo
Document Type: 
Article

Files in This Item:
File
Size





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.